All Oncology News

Mayo Clinic researchers report on a new surgical platform used during surgery that informs decision-making about tumor treatment within minutes.

Zanubrutinib was associated with improved cost savings and quality-adjusted life year benefits vs acalabrutinib in B-cell malignancies.

Arsenic trioxide plus all-trans retinoic acid & idarubicin improved EFS vs standard ATRA and anthracycline-based chemotherapy in high-risk APL.

Adding fixed-duration glofitamab-gxbm (Columvi) to gemcitabine and oxaliplatin led to a statistically significant and clinically meaningful improvement in survival vs rituximab (Rituxan) plus gemcitabine/oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.

The FDA has approved blinatumomab (Blincyto) for use in select patients with CD19+ Ph– B-cell precursor acute lymphoblastic leukemia in the consolidation phase.

The FDA had approved durvalumab plus, followed by single-agent durvalumab, for dMMR primary advanced or recurrent endometrial cancer.

Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.

The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.

Englumafusp alfa plus glofitamab showed activity and tolerability in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.

The CD7-targeted CAR T-cell therapy WU-CART-007 had a manageable safety profile and elicited preliminary efficacy signals in relapsed/refractory T-ALL/LBL.

Time from diagnosis, elevated WBC count, and VAF were all significantly associated with an increased risk of disease progression of polycythemia vera.

Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Zanubrutinib/venetoclax elicited a 100% overall response rate in untreated chronic lymphocytic leukemia harboring 17p deletions or TP53 mutations.

Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower tumor burden.

Marie Hu, MD, discusses considerations for the use of CAR T-cell therapy and bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma.

Luspatercept elicited superior erythroid response rates and duration of RBC transfusion independence compared with epoetin alfa in lower-risk MDS.

Minoo Battiwalla, MD, MS, discusses the impact of earlier-line FDA approvals for CAR T-cell therapies on treatment outcomes in multiple myeloma.

VK Gadi, MD, PhD, discusses findings from the DESTINY-Breast06 trial and the implications for hormone receptor–positive, HER2-low metastatic breast cancer.

The FDA granted accelerated approval to repotrectinib (Augtyro) for select patients with solid tumors harboring a NTRK gene fusion.

The FDA granted fast track designation to IBI343 monotherapy for relapsed/refractory advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

Venetoclax plus obinutuzumab with or without ibrutinib significantly improved PFS vs chemoimmunotherapy and vs venetoclax plus rituximab in frontline CLL.

Eric Vallieres, MD, FRCSC, discusses the evolving role of surgery in lung cancer treatment following the implementation of new neoadjuvant and adjuvant treatments.

The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer.

Decreases in variant allele frequency in ctDNA were linked to improved CBR with imlunestrant in estrogen receptor–positive, HER2-negative breast cancer

A case study details the importance of genomic testing in identifying cancer and guiding targeted treatment decisions that enhance overall survival.

Next generation capecitabine led to positive preliminary efficacy results in patients with stage III or IV gastrointestinal tract cancer.

Eric Winer, MD, discusses the safety and efficacy outcomes of the TakeAim Leukemia trial and future research with emavusertib in combination therapies.